Authors
Latest:
Future Research and Development of Abiraterone Combination TherapiesIn this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.
Latest:
Expert urges widespread adoption of next-generation sequencing among physiciansNGS empowers clinicians to take proactive measures to prevent disease, enables more precise diagnosis, and provides better insight on the best treatment option.
Latest:
Managing post-prostatectomy incontinence in patients with comorbidities"Most of these comorbidities, while they do affect the bladder, don't seem to affect the surgeries for stress urinary incontinence," says Jaspreet S. Sandhu, MD.
Latest:
UT Money Matters: Roth IRA conversionsExpert insight on pros, cons and optimal strategies when considering converting a traditional IRA to a Roth IRA.
Latest:
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures“I would say the take-home message for this study is that prescribing tamsulosin for a week prior to an anticipated surgery that involves flexible ureteroscopy is a very simple practice that certainly is within standard of care within pediatric urology," says Kate H. Kraft, MD, MHPE, FACS, FAAP.
Latest:
Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease“We have to understand as providers that we're not going to be the one and only conduit for this information anymore, which is a good thing, to be honest," says Ian Metzler, MD, MTM.
Latest:
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape“I think we now have really robust data showing that earlier treatment intensification with combination regimens does lead to improved survival for patients with metastatic hormone-sensitive prostate cancer," says Dr Louise Kostos.
Latest:
How to implement an ERAS pathway in your urology practiceProgram encompasses patient counseling, anesthetic planning, and early mobilization.
Latest:
Kari Bailey, MD, on the evolving priorities of women in urology"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.
Latest:
How to approach immune checkpoint inhibitor therapy in prostate cancerNext-generation sequencing identifies subtypes that may benefit from immune checkpoint inhibitors.
Latest:
Discover the Art and Science Behind Nerve Sparing Prostate SurgeryIn his latest YouTube masterclass, Dr. Ash Tewari shares his groundbreaking approach to nerve sparing prostate surgery, shedding light on the anatomy, surgical techniques, and innovations that make it possible.
Latest:
Experts urge FDA to remove black box warning on low-dose vaginal estrogenIn a panel meeting convened by the FDA, experts urged the agency to revise or remove the outdated boxed warning on hormone therapies for menopause.
Latest:
Emerging Therapies for Metastatic Castration-Resistant Prostate CancerRobert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.
Latest:
The Logistical Challenges in ccRCC TreatmentPanelists discuss how the logistical challenge of the new test requiring separate appointments (tracer injection followed by imaging 5 days later) is offset by scheduling flexibility because of the tracer’s 78-hour half-life and the technology essentially providing a “virtual biopsy” without invasive procedures.
Latest:
Future Perspectives in the Treatment of Patients With Urinary StonesDrs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.
Latest:
Jindan Yu, MD, highlights ongoing prostate cancer research projects"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD.
Latest:
The benefits of working with a consultant when starting a private urology practice"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching.
Latest:
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New FrontierNeal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Pooja Ghatalia, MD, on interim findings from RETAIN-2 trial in MIBC"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Is there a difference between MD and DO in urology?"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.
Latest:
Diversity in Urology: Progress made, but there is more work to be doneKelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.
Latest:
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD.
Latest:
Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practiceIn this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.
